Injections, Intra-Arterial

4 trials

Sponsors

Center of Molecular Immunology (CIM), Center of Molecular Inmunology (CIM)

Conditions

Hepatocellular carcinomaMetastatic breast tumorMetastatic breast tumors.Primary malignant colon and breast lesion and metastatic liver lesions.

Phase 1

hR3 MAb in combination with chemo-embolization in hepatocellular carcinoma.

RecruitingRPCEC00000022

Center of Molecular Immunology (CIM)Hepatocellular carcinoma

Start: 2007-01-02Target: 15Updated: 2026-03-30

Phase 2

99mTc-marked 14F7 MaB in metastatic breast, phase II

RecruitingRPCEC00000025

Center of Molecular Inmunology (CIM)Metastatic breast tumor

Start: 2005-10-29Target: 21Updated: 2026-03-30

hR3 monoclonal antibody combined with chemoembolization in mestatatic liver treatment.

RecruitingRPCEC00000023

Center of Molecular Immunology (CIM)Primary malignant colon and breast lesion and metastatic liver lesions.

Start: 2006-09-29Target: 15Updated: 2026-03-30

14F7 MAb marked with Tc99 Phase II in breast tumors.

Active, not recruitingRPCEC00000024

Center of Molecular Immunology (CIM)Metastatic breast tumors.

Start: 2003-02-13Target: 15Updated: 2026-03-30